The Cooper Companies, Inc. (NASDAQ:COO) Stock Has Consensus Price Target of $68.60

The Cooper Companies, Inc. (NASDAQ:COO) has earned an average rating of “Hold” from the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $68.60.

A number of equities research analysts have issued reports on the stock. Robert W. Baird set a $61.00 price objective on shares of Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. Needham & Company LLC dropped their target price on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Thursday, September 10th. JPMorgan Chase & Co. cut their price target on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a report on Thursday, September 10th. Weiss Ratings raised shares of Cooper Companies from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, September 18th. Finally, Mizuho set a $75.00 price target on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Lawrence Kurzius bought 10,000 shares of the business’s stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the completion of the purchase, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Walter Rosebrough, Jr. bought 7,000 shares of Cooper Companies stock in a transaction on Friday, September 11th. The stock was acquired at an average cost of $54.11 per share, for a total transaction of $378,770.00. Following the acquisition, the director owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 34,701 shares of company stock worth $1,880,039 over the last three months. Corporate insiders own 2.08% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors have recently modified their holdings of COO. Nisa Investment Advisors LLC grew its holdings in shares of Cooper Companies by 84.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 192,454 shares of the medical device company’s stock valued at $10,879,000 after purchasing an additional 88,216 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in Cooper Companies by 834.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 112,677 shares of the medical device company’s stock worth $6,370,000 after purchasing an additional 100,621 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Cooper Companies by 84.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 52,747 shares of the medical device company’s stock worth $2,982,000 after purchasing an additional 24,084 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Cooper Companies during the 3rd quarter worth approximately $2,669,000. Finally, Trail Ridge Investment Advisors LLC lifted its stake in Cooper Companies by 17.1% in the 3rd quarter. Trail Ridge Investment Advisors LLC now owns 12,293 shares of the medical device company’s stock valued at $695,000 after purchasing an additional 1,793 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Stock Performance

COO opened at $59.12 on Wednesday. The firm has a market cap of $11.24 billion, a P/E ratio of 20.18, a price-to-earnings-growth ratio of 2.37 and a beta of 0.83. Cooper Companies has a 52-week low of $51.01 and a 52-week high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The business’s fifty day moving average is $62.74 and its 200-day moving average is $65.94.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. Cooper Companies’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts expect that Cooper Companies will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a stock repurchase plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This buyback authorization permits the medical device company to buy up to 22.7% of its shares through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.